Clinical Trial Update: Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of GSK2646264 in urticaria completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urticaria

Drugs mentioned

• GSK2646264

Snippet

Sponsor: GlaxoSmithKline | Conditions: Urticaria | Phase 1 | Status: COMPLETED | Results posted: 2019-06-21